Vaishali Sanchorawala

List of Publications by Year
in descending order

253 papers	9,725 citations	50276 46 h-index	42399 92 g-index
256 all docs	256 docs citations	256 times ranked	4451 citing authors

#	Article	IF	Citations
1	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	4.1	1,179
2	High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study. Annals of Internal Medicine, 2004, 140, 85.	3.9	539
3	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	30.5	350
4	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 2012, 26, 2317-2325.	7.2	332
5	Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood, 1998, 91, 3662-3670.	1.4	323
6	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	27.0	268
7	Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 2007, 109, 492-496.	1.4	262
8	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352.	1.4	259
9	Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood, 2001, 97, 1885-1887.	1.4	200
10	Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1331-1341.	4.5	191
11	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 2011, 118, 865-873.	1.4	161
12	Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica, 2013, 98, 141-146.	3.5	155
13	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood, 2007, 110, 3561-3563.	1.4	154
14	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 2009, 114, 1489-1497.	1.4	153
15	An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation, 2001, 28, 637-642.	2.4	149
16	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	1.4	146
17	Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chainâ€“Associated (AL) Amyloidosis. Clinical Lymphoma and Myeloma, 2003, 3, 241-246.	2.1	137
18	Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood, 2019, 133, 215-223.	1.4	118

#	Article	IF	Citations
19	Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood, 2016, 128, 1059-1062.	1.4	117
20	Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood, 2020, 135, 1541-1547.	1.4	111
21	Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosisâ€"Associated Renal Disease. Annals of Internal Medicine, 2001, 134, 746.	3.9	111
22	Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 2004, 104, 1888-1893.	1.4	109
23	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood, 2015, 126, 2345-2347.	1.4	109
24	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605.	1.4	108
25	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 62-67.	3.0	108
26	High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 2004, 33, 381-388.	2.4	107
27	Persistent Pleural Effusions in Primary Systemic Amyloidosis. Chest, 2003, 124, 969-977.	0.8	106
28	Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure. Transplantation, 2010, 90, 905-911.	1.0	103
29	Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology Dialysis Transplantation, 2011, 26, 881-886.	0.7	99
30	Update on treatment of light chain amyloidosis. Haematologica, 2014, 99, 209-221.	3.5	93
31	Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 2005, 36, 597-600.	2.4	92
32	Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.. Blood, 2004, 104, 942-942.	1.4	82
33	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia, 2016, 30, 1979-1986.	7.2	73
34	Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal of Haematology, 1999, 104, 553-559.	2.5	68
35	Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney International, 2003, 63, 1868-1873.	5.2	63
36	Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 339-343.	2.4	62

#	Article	IF	Citations
37	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood, 2014, 124, 2498-2506.	1.4	62
38	Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1057-1064.	1.2	60
39	High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney International, 2003, 63, 1051-1057.	5.2	59
40	Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood, 2010, 116, 5071-5072.	1.4	59
41	Long-term outcome of kidney transplantation in AL amyloidosis. Kidney International, 2019, 95, 405-411.	5.2	57
42	Spontaneous rupture of the spleen in AL amyloidosis. American Journal of Hematology, 2003, 74, 131-135.	4.1	56
43	Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1445-1451.	2.0	55
44	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ¹⁸F-Florbetapir PET/CT. Journal of Nuclear Medicine, 2019, 60, 1234-1239.	5.0	54
45	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10.	6.2	53
46	Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 2013, 98, 789-792.	3.5	50
47	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 1-2.	3.0	49
48	AL amyloidosis associated with B-cell lymphoproliferative disorders: Frequency and treatment outcomes. American Journal of Hematology, 2006, 81, 692-695.	4.1	47
49	Localized amyloidosis of the breast: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 72-75.	3.0	47
50	Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 2002, 117, 886-889.	2.5	46
51	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 645-645.	1.4	46
52	Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal, 2021, 11, 139.	6.2	45
53	Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 210-215.	3.0	44
54	Myocardial infarction with â€œclean coronariesâ€•caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 160-164.	3.0	42

#	Article	IF	Citations
55	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7.	3.0	42
56	Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplantation, 2014, 49, 434-439.	2.4	41
57	Improved Quantification of CardiacÂAmyloid Burden in SystemicÂLight ChainÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1325-1336.	5.3	41
58	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 957-970.	0.5	40
59	Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Advances, 2020, 4, 880-884.	5.2	40
60	Association of acquired von Willebrand syndrome with AL amyloidosis. American Journal of Hematology, 2007, 82, 363-367.	4.1	39
61	High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood, 2012, 120, 4445-4446.	1.4	38
62	Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica, 2011, 96, 1890-1892.	3.5	34
63	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	1.4	34
64	Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2005, 35, 567-575.	2.4	33
65	Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood, 2006, 108, 3945-3947.	1.4	33
66	Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplantation, 2007, 40, 557-562.	2.4	33
67	Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood, 2010, 116, 1990-1991.	1.4	33
68	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology, 2020, 38, 1455-1462.	1.6	31
69	High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 127-132.	2.0	31
70	Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood, 2017, 130, 1383-1386.	1.4	30
71	An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 261-269.	3.0	29
72	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	7.2	29

#	Article	IF	Citations
73	Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leukemia and Lymphoma, 2008, 49, 1108-1115.	1.3	28
74	Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 130-131.	3.0	27
75	A longitudinal evaluation of healthâ€related quality of life in patients with <scp>AL</scp> amyloidosis: associations with health outcomes over time. British Journal of Haematology, 2017, 179, 461-470.	2.5	27
76	Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 244-249.	3.0	27
77	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	1.4	27
78	New Hematologic Response Criteria Predict Survival in Patients With Immunoglobulin Light Chain Amyloidosis Treated With High-Dose Melphalan and Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 2749-2750.	1.6	26
79	Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. European Journal of Haematology, 2020, 105, 495-501.	2.2	26
80	Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica, 2009, 94, 1029-1032.	3.5	25
81	Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Advances, 2019, 3, 216-218.	5.2	25
82	Establishment of brain natriuretic peptide â€•based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. British Journal of Haematology, 2020, 188, 424-427.	2.5	25
83	Lymphadenopathy as a manifestation of amyloidosis: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 256-260.	3.0	24
84	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17.	3.0	22
85	Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer Journal, 2020, 10, 118.	6.2	21
86	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood, 2014, 124, 3450-3450.	1.4	21
87	Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 528-542.	0.9	20
88	Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplantation, 2013, 48, 1537-1542.	2.4	20
89	Macroglossia â€“ not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 83-86.	3.0	19
90	Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 229-235.	3.0	19

#	Article	IF	Citations
91	Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica, 2016, 101, 86-90.	3.5	19
92	High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Acta Haematologica, 2020, 143, 381-387.	1.4	19
93	A Case of Atypical Light Chain Deposition Diseaseâ€"Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 858-867.	4.5	18
94	Oral Cyclic Melphalan and Dexamethasone for Patients With AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 469-472.	0.4	18
95	Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 188-193.	3.0	18
96	Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 1-7.	3.0	18
97	Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia, 2021, 35, 916-919.	7.2	18
98	Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation, 2001, 28, 1105-1109.	2.4	17
99	Amyloidotic Cardiomyopathy: Multidisciplinary Approach to Diagnosis and Treatment. Heart Failure Clinics, 2011, 7, 385-393.	2.1	17
100	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	2.5	17
101	Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 103-107.	3.0	16
102	High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Hematology/Oncology Clinics of North America, 2014, 28, 1131-1144.	2.2	16
103	Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2016, 91, E458-60.	4.1	16
104	Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Related Outcome Measures, 2017, Volume 8, 157-167.	1.2	16
105	Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 37-41.	3.0	15
106	Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. American Journal of Transplantation, 2019, 19, 3185-3190.	4.7	15
107	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.. Journal of Clinical Oncology, 2021, 39, 8003-8003.	1.6	15
108	A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2014, 124, 4741-4741.	1.4	15

#	Article	IF	Citations
109	Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology, 2010, 89, 579-584.	1.8	14
110	A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplantation, 2011, 46, 976-980.	2.4	14
111	A new era of amyloidosis: the trends at a major US referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 192-196.	3.0	14
112	Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, e169-e173.	2.0	14
113	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1998-2009.	6.4	14
114	Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer Journal, 2020, 10, 88.	6.2	14
115	Amyloid Deposits in the Bone Marrow of Patients with Immunoglobulin Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment. Biology of Blood and Marrow Transplantation, 2012, 18, 1935-1938.	2.0	13
116	The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplantation, 2017, 52, 1349-1351.	2.4	13
117	A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 148-155.	3.0	13
118	Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis.. Journal of Clinical Oncology, 2010, 28, 8024-8024.	1.6	13
119	Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplantation, 2011, 46, 161-162.	2.4	12
120	The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1729-1732.	2.0	12
121	The six-minute walk test in patients with AL amyloidosis: a single centre case series. British Journal of Haematology, 2017, 177, 388-394.	2.5	12
122	Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 1823-1827.	2.0	12
123	Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 156-159.	3.0	12
124	Prevalence and prognostic value of Dâ€dimer elevation in patients with AL amyloidosis. American Journal of Hematology, 2019, 94, 1098-1103.	4.1	12
125	Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25â€year longitudinal study. American Journal of Hematology, 2022, 97, 1189-1199.	4.1	12
126	Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 149-153.	3.0	11

#	Article	IF	Citations
127	Bortezomib ocular toxicities: Outcomes with ketotifen. American Journal of Hematology, 2019, 94, E80-E82.	4.1	11
128	The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney International Reports, 2020, 5, 485-493.	0.8	11
129	Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following StemÂCell Transplantation. JACC: CardioOncology, 2020, 2, 721-731.	4.0	11
130	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. Blood, 2020, 136, 48-50.	1.4	11
131	Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 156-160.	3.0	10
132	Once AL amyloidosis: not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 139-140.	3.0	10
133	Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).. Blood, 2006, 108, 3094-3094.	1.4	10
134	Predictive factors of outcomes in patients with <scp>AL</scp> amyloidosis treated with daratumumab. American Journal of Hematology, 2022, 97, 79-89.	4.1	10
135	Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. HemaSphere, 2022, 6, e681.	2.7	10
136	Diaphragm paralysis in primary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 193-196.	3.0	9
137	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 268.	2.7	9
138	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 214-220.	3.0	8
139	Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives . Journal of Blood Medicine, 2019, Volume 10, 373-380.	1.7	8
140	The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 17-24.	3.0	8
141	Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study. Blood, 2018, 132, 2005-2005.	1.4	8
142	Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). Journal of Clinical Oncology, 2007, 25, 8050-8050.	1.6	8
143	Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 184-189.	3.0	8
144	Daratumumab in AL amyloidosis. Blood, 2022, 140, 2317-2322.	1.4	8

#	Article	IF	Citations
145	Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. American Journal of Hematology, 2020, 95, E45-E48.	4.1	7
146	Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1099-1113.	2.2	7
147	Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrology Dialysis Transplantation, 2022, 37, 1281-1288.	0.7	7
148	Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546.	1.6	7
149	Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).. Blood, 2004, 104, 923-923.	1.4	7
150	High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 127-129.	3.0	6
151	A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 127-130.	3.0	6
152	Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis. Bone Marrow Transplantation, 2014, 49, 1345-1346.	2.4	6
153	Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 124-127.	3.0	6
154	Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation, 2016, 51, 1318-1322.	2.4	6
155	Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2018, 93, E129-E132.	4.1	6
156	AL Amyloidosis in Myeloma: Red Flag Symptoms. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 777-778.	0.4	6
157	Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer Journal, 2021, 11, 117.	6.2	6
158	Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. American Journal of Blood Research, 2012, 2, 9-17.	0.6	6
159	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 2022, 15, 594-603.	5.3	6
160	Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS8076-TPS8076.	1.6	6
161	Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. American Journal of Hematology, 2013, 88, 719-719.	4.1	5
162	Echocardiography and Survival in Light Chain Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007826.	2.6	5

#	Article	IF	Citations
163	Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis. American Journal of Hematology, 2019, 94, E194-E196.	4.1	5
164	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. Blood, 2020, 136, 37-40.	1.4	5
165	Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 3480-3480.	1.4	5
166	Amyloidomics comes of age. Blood, 2012, 119, 1795-1796.	1.4	4
167	Microbiologically documented infections in patients undergoing highâ€dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transplant Infectious Disease, 2013, 15, 187-194.	1.7	4
168	Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. American Journal of Hematology, 2014, 89, 706-708.	4.1	4
169	Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2018, 53, 371-373.	2.4	4
170	Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. Blood, 2018, 132, 755-757.	1.4	4
171	High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplantation, 2019, 54, 1304-1309.	2.4	4
172	Cardiac biomarkers and healthâ€related quality of life in patients with light chain (<scp>AL</scp>) amyloidosis. British Journal of Haematology, 2019, 185, 998-1001.	2.5	4
173	A pharmacistâ€™s review of the treatment of systemic light chain amyloidosis. Journal of Oncology Pharmacy Practice, 2021, 27, 187-198.	0.9	4
174	Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 425-426.	0.4	4
175	Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.. Blood, 2004, 104, 5226-5226.	1.4	4
176	Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation. Blood, 2012, 120, 2019-2019.	1.4	4
177	Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. Kidney Medicine, 2022, 4, 100427.	2.0	4
178	Penile ulcers complicating systemic AL amyloidosis: a case report. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 203-204.	3.0	3
179	Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact. Blood, 2019, 134, 4758-4758.	1.4	3
180	Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis. Blood, 2010, 116, 3021-3021.	1.4	3

#	Article	IF	Citations
181	Healthâ€related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasoneâ€‰Â±â€‰daratumumab: Results from the <scp>ANDROMEDA</scp> study. American Journal of Hematology, 2022, 97, 719-730.	4.1	3
182	Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a â€˜melphalan recallâ€™ reaction. Bone Marrow Transplantation, 2010, 45, 21-24.	2.4	2
183	REDUCTION IN VENTRICULAR WALL THICKNESS FOLLOWING HIGH-DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANTATION FOR AL CARDIAC AMYLOIDOSIS. Journal of the American College of Cardiology, 2010, 55, A36.E351.	2.8	2
184	Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 156-162.	3.0	2
185	Nonoperative Management of Spontaneous Splenic Rupture in a Patient with Light-Chain Amyloidosis: A Case Report. Journal of Vascular and Interventional Radiology, 2015, 26, 1578-1580.	0.5	2
186	High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. Bone Marrow Transplantation, 2018, 53, 1593-1595.	2.4	2
187	Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 113-114.	3.0	2
188	Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e460-e463.	0.4	2
189	The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study. Blood, 2019, 134, 4353-4353.	1.4	2
190	Durable Responses to Lenalidomide (RevlimidÂ®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.. Blood, 2007, 110, 192-192.	1.4	2
191	A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease. Blood, 2014, 124, 4767-4767.	1.4	2
192	Symptoms of Depression and Anxiety Assessed By the SF-36 Questionnaire in Patients with AL Amyloidosis. Blood, 2015, 126, 3299-3299.	1.4	2
193	Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation. American Journal of Medicine, 2022, 135, S30-S37.	1.5	2
194	A novel substitution of proline (P32L) destabilises Î²2-microglobulin inducing hereditary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, , 1-8.	3.0	2
195	Optimal dosing of high-dose melphalan prior to autologous hematopoietic stem cell transplantation in a patient with AL amyloidosis and a solitary kidney. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 86-88.	0.9	1
196	Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfusion and Apheresis Science, 2018, 57, 411-415.	1.0	1
197	Safety of autologous stem cell transplantation in patients with known Human Tâ€cell Lymphotropic Viruses Type 1 and 2 infection: A case series of four patients. American Journal of Hematology, 2019, 94, E317-E319.	4.1	1
198	Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study. Blood, 2019, 134, 4578-4578.	1.4	1

#	Article	IF	Citations
199	Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.. Blood, 2009, 114, 4353-4353.	1.4	1
200	High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis. Blood, 2010, 116, 3553-3553.	1.4	1
201	Macroglossia â€“ Not Always AL Amyloidosis. Blood, 2010, 116, 5007-5007.	1.4	1
202	Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center. Blood, 2013, 122, 3328-3328.	1.4	1
203	The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. Blood, 2015, 126, 5490-5490.	1.4	1
204	Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 4523-4523.	1.4	1
205	A phase II trial of lenalidomide for patients with AL amyloidosis. Journal of Clinical Oncology, 2006, 24, 7524-7524.	1.6	1
206	Treatment of Al Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation. , 2004, , 124-126.		1
207	AL (Immunoglobulin Light-Chain) Amyloidosis. , 2008, , 551-569.		1
208	Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394.	1.4	1
209	Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT). Blood, 2011, 118, 2041-2041.	1.4	1
210	Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115. Blood, 2011, 118, 2004-2004.	1.4	1
211	Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis. Blood, 2013, 122, 1991-1991.	1.4	1
212	Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	1
213	Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis. Bone Marrow Transplantation, 2015, 50, 868-869.	2.4	0
214	David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957â€“2015. Bone Marrow Transplantation, 2016, 51, 323-323.	2.4	0
215	A Woman in Her 40s With Headache and New-Onset Seizures. JAMA Neurology, 2017, 74, 476.	9.0	0
216	Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation. , 2004, , 124-126.		0

#	Article	IF	Citations
217	Quantitative Serum Free Light-Chain Assay in the Diagnostic Evaluation of Al Amyloidosis. , 2004, , 90-92.		0
218	Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.. Blood, 2004, 104, 2393-2393.	1.4	0
219	Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.. Blood, 2005, 106, 4078-4078.	1.4	0
220	High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.. Blood, 2005, 106, 5476-5476.	1.4	0
221	Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.. Blood, 2005, 106, 1160-1160.	1.4	0
222	Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.. Blood, 2006, 108, 612-612.	1.4	0
223	Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.. Blood, 2007, 110, 2873-2873.	1.4	0
224	Localized AL Amyloidosis of the Breast: A Case Series.. Blood, 2009, 114, 4906-4906.	1.4	0
225	Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.. Blood, 2009, 114, 2318-2318.	1.4	0
226	Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.. Blood, 2009, 114, 4352-4352.	1.4	0
227	Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.. Blood, 2009, 114, 1883-1883.	1.4	0
228	Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.. Blood, 2009, 114, 4356-4356.	1.4	0
229	Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis. Blood, 2010, 116, 3022-3022.	1.4	0
230	High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement. Blood, 2011, 118, 2043-2043.	1.4	0
231	Melphalan, Lenalidomide and Dexamethasone Combination Therapy In Patients with AL Amyloidosis. Blood, 2011, 118, 2924-2924.	1.4	0
232	Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide. Blood, 2012, 120, 1873-1873.	1.4	0
233	Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial. Blood, 2012, 120, 4084-4084.	1.4	0
234	Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.. Journal of Clinical Oncology, 2013, 31, 8545-8545.	1.6	0

#	Article	IF	Citations
235	Proteasome Inhibitor Based Protocol For Antibody Mediated Rejection In Kidney Transplantation. Blood, 2013, 122, 4728-4728.	1.4	0
236	Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study. Blood, 2014, 124, 3463-3463.	1.4	0
237	Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients. Blood, 2014, 124, 4750-4750.	1.4	0
238	Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio. Blood, 2015, 126, 2956-2956.	1.4	0
239	Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients. Blood, 2015, 126, 5499-5499.	1.4	0
240	A Retrospective Review of Engraftment Data for Tbo-Filgrastim Vs. Filgrastim in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation. Blood, 2015, 126, 5484-5484.	1.4	0
241	Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis. Blood, 2018, 132, 4616-4616.	1.4	0
242	The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades. Blood, 2018, 132, 5536-5536.	1.4	0
243	Successful transition from bortezomib subcutaneous to generic intravenous bortezomib: Cost savings initiative with global economic impact.. Journal of Clinical Oncology, 2020, 38, e19375-e19375.	1.6	0
244	Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab. Blood, 2021, 138, 2734-2734.	1.4	0
245	Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis. Bone Marrow Transplantation, 2021, , .	2.4	0
246	Beyond Survival in AL amyloidosis: Identifying and Satisfying Patientsâ€™ Needs. Hemato, 2022, 3, 38-46.	0.6	0
247	Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes. Blood, 2020, 136, 51-51.	1.4	0
248	Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments. Blood, 2020, 136, 38-39.	1.4	0
249	Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications. Blood, 2020, 136, 23-24.	1.4	0
250	Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Blood, 2020, 136, 4-5.	1.4	0
251	AL amyloidosis: who, what, when, why, and where. Oncology, 2012, 26, 164, 166, 169.	0.5	0
252	Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. British Journal of Haematology, 2022, , .	2.5	0

#	Article	IF	Citations
253	Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer Journal, 2022, 12, .	6.2	0